1 / 5

Working group

Working group. Product selection issues. GF PSM Plans. Can the list of medicines be revised once PSM plans have been approved? Introduction of OI drugs (SA) revision of guidelines (EG) latency period with needs in additional ARVs and before guidelines be up-dated

yanni
Download Presentation

Working group

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Working group Product selection issues

  2. GF PSM Plans • Can the list of medicines be revised once PSM plans have been approved? • Introduction of OI drugs (SA) • revision of guidelines (EG) • latency period with needs in additional ARVs and before guidelines be up-dated • What is the process to get the approval from GF? LFA, PR, Port-Folio?

  3. Condoms procurement requirements • Clarification needed on WB requirements (Tanzania) • How countries in the room have responded to WB requirements of a pre qualified list of manufacturers ?

  4. ARV paediatrics • WHO Pre-qualified list: too few paediatric formulations (Uganda) • Not registered at country level

  5. Other issues • GF: notion of stringent authorities (SA) • Clinton Foundation: match between the pricing list and WHO pre-qualified list

More Related